Cantor Fitzgerald restated an overweight rating for Anteris Technologies Global Corp. on October 8, 2026.
1 report, 1 independent
Updated 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald restated an overweight rating for Anteris Technologies Global Corp. on October 8, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma on August 20, 2025.
- Cantor Fitzgerald reiterated an Overweight rating on Amazon stock.
- Cantor Fitzgerald and Citigroup issued rating updates, while MarketBeat reported research notes on Quince Therapeutics.
- Cantor Fitzgerald set a neutral rating on Merck & Co., Inc. on September 12, 2026.
- Cantor Fitzgerald restated an overweight rating on shares, while J. Goldman & Co LP purchased a new stake in Annexon. Disclosure was made to the Securities and Exchange Commission.